Regeneron Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Regeneron Pharmaceuticals has been growing earnings at an average annual rate of 15.8%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 18.1% per year. Regeneron Pharmaceuticals's return on equity is 15.2%, and it has net margins of 30.1%.
Key information
15.8%
Earnings growth rate
16.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 18.1% |
Return on equity | 15.2% |
Net Margin | 30.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Oct 25Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price
Aug 07Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet
Jul 17Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Apr 17Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price
Feb 03Revenue & Expenses BreakdownBeta
How Regeneron Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 13,117 | 3,954 | 2,631 | 0 |
30 Sep 23 | 13,097 | 3,991 | 2,554 | 0 |
30 Jun 23 | 12,671 | 4,299 | 2,443 | 0 |
31 Mar 23 | 12,370 | 4,183 | 2,267 | 0 |
31 Dec 22 | 12,173 | 4,338 | 2,116 | 0 |
30 Sep 22 | 13,710 | 5,370 | 2,015 | 0 |
30 Jun 22 | 14,227 | 5,687 | 1,931 | 0 |
31 Mar 22 | 16,508 | 7,934 | 1,869 | 0 |
31 Dec 21 | 16,072 | 8,075 | 1,825 | 0 |
30 Sep 21 | 13,543 | 6,996 | 1,569 | 0 |
30 Jun 21 | 12,384 | 6,205 | 1,451 | 0 |
31 Mar 21 | 9,198 | 4,004 | 1,384 | 0 |
31 Dec 20 | 8,497 | 3,513 | 1,346 | 0 |
30 Sep 20 | 7,938 | 3,156 | 1,459 | 0 |
30 Jun 20 | 7,387 | 2,984 | 1,437 | 0 |
31 Mar 20 | 7,013 | 2,279 | 1,383 | 0 |
31 Dec 19 | 6,558 | 2,116 | 1,342 | 0 |
30 Sep 19 | 6,622 | 2,144 | 1,381 | 0 |
30 Jun 19 | 6,542 | 2,069 | 1,446 | 0 |
31 Mar 19 | 6,572 | 2,428 | 1,517 | 0 |
31 Dec 18 | 5,146 | 2,444 | 1,127 | 0 |
30 Sep 18 | 6,365 | 1,798 | 1,475 | 0 |
30 Jun 18 | 6,203 | 1,591 | 1,412 | 0 |
31 Mar 18 | 6,065 | 1,428 | 1,354 | 0 |
31 Dec 17 | 5,872 | 1,199 | 1,320 | 0 |
30 Sep 17 | 5,517 | 1,278 | 1,236 | 0 |
30 Jun 17 | 5,236 | 1,155 | 1,200 | 0 |
31 Mar 17 | 4,979 | 963 | 1,185 | 0 |
31 Dec 16 | 4,860 | 896 | 1,178 | 0 |
30 Sep 16 | 4,732 | 797 | 1,147 | 0 |
30 Jun 16 | 4,649 | 743 | 1,087 | 0 |
31 Mar 16 | 4,435 | 741 | 969 | 0 |
31 Dec 15 | 4,104 | 636 | 839 | 0 |
30 Sep 15 | 3,808 | 571 | 719 | 0 |
30 Jun 15 | 3,396 | 444 | 653 | 0 |
31 Mar 15 | 3,063 | 346 | 575 | 0 |
31 Dec 14 | 2,820 | 338 | 519 | 0 |
30 Sep 14 | 2,628 | 345 | 426 | 0 |
30 Jun 14 | 2,499 | 403 | 380 | 0 |
31 Mar 14 | 2,291 | 394 | 355 | 0 |
31 Dec 13 | 2,105 | 414 | 346 | 0 |
30 Sep 13 | 1,909 | 798 | 305 | 0 |
30 Jun 13 | 1,740 | 848 | 254 | 0 |
31 Mar 13 | 1,586 | 837 | 230 | 0 |
Quality Earnings: REGN has high quality earnings.
Growing Profit Margin: REGN's current net profit margins (30.1%) are lower than last year (35.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REGN's earnings have grown by 15.8% per year over the past 5 years.
Accelerating Growth: REGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: REGN had negative earnings growth (-8.9%) over the past year, making it difficult to compare to the Biotechs industry average (-8.9%).
Return on Equity
High ROE: REGN's Return on Equity (15.2%) is considered low.